Peptides as a therapeutic modality attract much attention due to their synthetic accessibility,
high degree of specific binding, and the ability to target protein surfaces traditionally …

Over the past decade, peptide drug discovery has experienced a revival of interest and
scientific momentum, as the pharmaceutical industry has come to appreciate the role that …

A large proportion of protein–protein interactions (PPIs) occur between a short peptide and a
globular protein domain; the peptides involved in surface interactions play important roles …

Peptides are a growing therapeutic class due to their unique spatial characteristics that can
target traditionally “undruggable” protein–protein interactions and surfaces. Despite their …

The clinical translation of cationic α-helical antimicrobial peptides (AMPs) has been
hindered by structural instability, proteolytic degradation and in vivo toxicity from nonspecific …

Protein–protein interactions (PPIs) are involved at all levels of cellular organization, thus
making the development of PPI inhibitors extremely valuable. The identification of selective …

Peptides and proteins are not orally bioavailable in mammals, although a few peptides are
intestinally absorbed in small amounts. Polypeptides are generally too large and polar to …

Membrane fusion triggered by Ca2+ is orchestrated by a conserved set of proteins to
mediate synaptic neurotransmitter release, mucin secretion and other regulated exocytic …

Our ever‐increasing understanding of biological systems is providing a range of exciting
novel biological targets, whose modulation may enable novel therapeutic options for many …

Protein structure underlies essential biological processes and provides a blueprint for
molecular mimicry that drives drug discovery. Although small molecules represent the lion's …